An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Sponsor: Eli Lilly and Company

Protocol F3Z-MC-IOQV(a)
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
NCT03368807
Approval Date: 20-Nov-2017

F3Z-MC-IOQV(a) Clinical Protocol 
Page 1 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
Protocol F3Z-MC-IOQV(a) 
An Objective Assessment of Mealtime Bolus Insulin 
Behavior and Associated Factors 
 
Confidential Information 
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation 
using the reusable insulin injection pen (LY8888AT), unless such persons are bound by a 
confidentiality agreement with Eli Lilly and Company or its subsidiaries.   
Note to Regulatory Authorities:  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries. 
Clinical Investigation Using the Reusable Insulin Injection Pen (LY8888AT) 
Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
Protocol Electronically Signed and Approved by Lilly on date provided below. 
 
Version 
Approval Date 
Original 
23 Sep 2017 
Amendment (a) 
20 Nov 2017 
 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 2 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
Table of Contents 
Section 
Page 
Protocol F3Z-MC-IOQV(a) An Objective Assessment of Mealtime Bolus 
Insulin Behavior and Associated Factors ................................................................................1 
Table of Contents .............................................................................................................................2 
1. 
Synopsis ...................................................................................................................................8 
2. 
Schedule of Activities ............................................................................................................11 
3. 
Introduction ...........................................................................................................................14 
3.1. 
Study Rationale ................................................................................................................14 
3.2. 
Background.......................................................................................................................14 
3.3. 
Benefit/Risk Assessment ..................................................................................................14 
4. 
Objectives and Endpoints ......................................................................................................15 
5. 
Study Design .........................................................................................................................16 
5.1. 
Overall Design ..................................................................................................................16 
5.1.1. 
Eligibility and Enrollment ........................................................................................16 
5.1.2. 
Study Period 1 ..........................................................................................................17 
5.1.3. 
Study Period 2 ..........................................................................................................17 
5.2. 
Number of Subjects ..........................................................................................................18 
5.3. 
End of Study Definition....................................................................................................18 
5.4. 
Scientific Rationale for Study Design ..............................................................................18 
5.5. 
Justification for Dose ........................................................................................................18 
6. 
Study Population ...................................................................................................................19 
6.1. 
Inclusion Criteria ..............................................................................................................19 
6.2. 
Exclusion Criteria .............................................................................................................20 
6.3. 
Lifestyle Restrictions ........................................................................................................21 
6.4. 
Screen Failures .................................................................................................................21 
7. 
Treatments .............................................................................................................................22 
7.1. 
Treatments Administered .................................................................................................22 
7.1.1. 
Packaging and Labeling ...........................................................................................22 
7.1.2. 
Medical Devices .......................................................................................................22 
7.1.2.1. 
Continuous Glucose Monitoring ........................................................................22 
7.1.2.2. 
Investigational Reusable Insulin Injection Pen ..................................................23 
7.2. 
Method of Treatment Assignment ....................................................................................23 
7.2.1. 
Selection and Timing of Doses ................................................................................23 
7.3. 
Blinding ............................................................................................................................23 
7.4. 
Dosage Modification ........................................................................................................23 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 3 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
7.5. 
Preparation/Handling/Storage/Accountability .................................................................23 
7.6. 
Treatment Compliance .....................................................................................................24 
7.7. 
Concomitant Therapy .......................................................................................................24 
7.8. 
Treatment after the End of the Study ...............................................................................24 
7.8.1. 
Treatment after Study Completion ...........................................................................24 
8. 
Discontinuation Criteria ........................................................................................................25 
8.1. 
Discontinuation from Study Treatment ............................................................................25 
8.1.1. 
Permanent Discontinuation from Study Treatment .................................................25 
8.1.2. 
Temporary Discontinuation from Study Treatment .................................................25 
8.1.3. 
Discontinuation of Inadvertently Enrolled Subjects ................................................25 
8.2. 
Discontinuation from the Study ........................................................................................25 
8.3. 
Lost to Follow-Up ............................................................................................................26 
9. 
Study Assessments and Procedures .......................................................................................27 
9.1. 
Efficacy Assessments .......................................................................................................27 
9.1.1. 
Primary Efficacy Assessments .................................................................................27 
9.1.2. 
Secondary Assessments ...........................................................................................27 
9.1.3. 
Exploratory Assessments .........................................................................................28 
9.1.3.1. 
Hypoglycemic Confidence Scale .......................................................................28 
9.1.3.2. 
Adult Low Blood Sugar Survey .........................................................................28 
9.1.3.3. 
The Big Five Inventory ......................................................................................28 
9.1.3.4. 
Health Problem Solving Scale ............................................................................29 
9.1.3.5. 
Pictorial Representation of Illness and Self Measure 
Revised II ...........................................................................................................29 
9.1.3.6. 
General Life Stress Scale ...................................................................................29 
9.1.4. 
Appropriateness of Assessments ..............................................................................29 
9.2. 
Adverse Events and Device Complaints ..........................................................................30 
9.2.1. 
Serious Adverse Events ...........................................................................................30 
9.2.1.1. 
Severe Hypoglycemia ........................................................................................32 
9.2.1.2. 
Suspected Unexpected Serious Adverse Reactions ...........................................32 
9.2.2. 
Adverse Device Effects ............................................................................................32 
9.2.3. 
Complaint Handling .................................................................................................32 
9.3. 
Treatment of Overdose .....................................................................................................33 
9.4. 
Safety ................................................................................................................................33 
9.4.1. 
Laboratory Tests ......................................................................................................33 
9.4.2. 
Safety Monitoring ....................................................................................................33 
10. Statistical Considerations ......................................................................................................34 
10.1. Sample Size Determination ..............................................................................................34 
10.2. Populations for Analyses ..................................................................................................34 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 4 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
10.3. Statistical Analyses ...........................................................................................................34 
10.3.1. 
General Statistical Considerations ...........................................................................34 
10.3.1.1. 
Treatment Group Comparability ........................................................................35 
10.3.1.2. 
Subject Disposition ............................................................................................35 
10.3.1.3. 
Subject Characteristics .......................................................................................35 
10.3.1.4. 
Treatment Compliance .......................................................................................35 
10.3.2. 
Efficacy Analyses ....................................................................................................35 
10.3.2.1. 
Primary Analyses ...............................................................................................35 
10.3.2.2. 
Secondary Analyses ...........................................................................................35 
10.3.3. 
Safety Analyses ........................................................................................................35 
10.3.4. 
Other Analyses .........................................................................................................35 
10.3.4.1. 
Subgroup Analyses .............................................................................................35 
10.3.5. 
Interim Analyses ......................................................................................................36 
11. References .............................................................................................................................37 
12. Appendices ............................................................................................................................39 
 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 5 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
List of Tables 
Table 
Page 
Table IOQV.1. 
Schedule of Activities .......................................................................................12 
Table IOQV.2. 
Objectives and Endpoints ..................................................................................15 
Table IOQV.3. 
Treatment Regimens ..........................................................................................22 
Table IOQV.4. 
Analysis Sets .....................................................................................................34 
 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 6 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
List of Figures 
Figure 
Page 
Figure IOQV.1. Illustration of study design for Clinical Protocol F3Z-MC-IOQV. ...................16 
Figure IOQV.2. Example of a missed injection using a CGM profile. .......................................27 
 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 7 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
List of Appendices 
Appendix 
Page 
Appendix 1. 
Abbreviations and Definitions ...........................................................................40 
Appendix 2. 
Study Governance Considerations ....................................................................43 
Appendix 3. 
Classification of Contraceptive Methods ..........................................................47 
Appendix 5. 
Summary of Protocol Amendments ..................................................................49 
 
CCI

F3Z-MC-IOQV(a) Clinical Protocol 
Page 8 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
1. Synopsis 
Title of Study:  
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors 
Rationale:   
Current diabetes management using basal/bolus insulin regimens requires a high level of patient 
engagement.  One-third of patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) reported 
insulin omission/nonadherence at least once in the past month.  Of those patients, there was an 
average of 3.3 days per month of insulin omission/nonadherence (Peyrot et al. 2012).  Patients 
often cite being too busy, fear of hypoglycemia, and concerns about weight gain as reasons for 
missing doses (Peyrot et al. 2012).  Downloaded dosage data from insulin pump users indicated 
that 65% of pump-using children/adolescents with T1D missed 1 or more mealtime insulin bolus 
doses per week, with an association between missed bolus doses and glycated hemoglobin 
(HbA1c) results (Burdick et al. 2004).  Prior to the development of insulin injection pens that 
track dose data, missed dosage data for multiple daily injection users was obtained by patient 
survey results only.  The reusable insulin injection pen that records doses affords the opportunity 
to objectively gather omitted or suboptimal insulin dose data via pen download.  Additionally, 
the use of continuous glucose monitoring (CGM) allows an assessment of the impact of bolus 
dosing on short-term glycemic control. 
Objective(s)/Endpoints: 
Objectives 
Endpoint(s) 
Primary 
• To objectively estimate the average number of days per 
month with a missed bolus dose in subjects with type 1 or 
type 2 diabetes with blinded CGM 
 
• The average number of days per month 
with a missed bolus dose 
Secondary 
• To estimate the average number of days per month with a 
missed bolus dose in subjects with type 1 or type 2 
diabetes with unblinded CGM 
• To estimate the percent time-in-range in subjects with type 
1 or type 2 diabetes with 
o 
Blinded CGM  
o 
Unblinded CGM 
• To estimate the percent of missed bolus doses in subjects 
with type 1 or type 2 diabetes with  
o 
Blinded CGM 
o 
Unblinded CGM 
• To estimate the average number of missed bolus doses per 
day in subjects with type 1 or type 2 diabetes with 
o 
Blinded CGM 
o 
Unblinded CGM 
• To estimate the Missed and Suboptimal Bolus Dose 
(MSBD) in subjects with type 1 or type 2 diabetes with  
o 
Blinded CGM  
o 
Unblinded CGM 
 
• The average number of days per month 
with a missed bolus dose 
 
• Percent time-in-range (glucose >70 and 
≤180 mg/dL) 
 
 
• Percent of missed bolus doses per month 
 
 
• Average number of missed bolus doses per 
day 
 
 
• The average number of MSBD events per 
month 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 9 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
Exploratory 
• To assess the association between MSBD rate and CGM 
alert settings  
• To evaluate characteristics associated with short-term 
glycemic control in subjects with type 1 or type 2 diabetes  
• To estimate the average number of days per month with a 
missed bolus dose in subjects with type 1 diabetes with  
o 
Blinded CGM  
o 
Unblinded CGM 
• To estimate the average number of days per month with a 
missed bolus dose in subjects with type 2 diabetes with  
o 
Blinded CGM  
o 
Unblinded CGM 
 
• Correlation between MSBD rate and CGM 
alert settings  
• Outcome for each PRO instrument* 
 
• The average number of days per month 
with a missed bolus dose 
 
 
• The average number of days per month 
with a missed bolus dose 
 
Abbreviations:  CGM = continuous glucose monitoring; PRO = patient-reported outcomes. 
* if available for use 
 
Summary of Study Design:   
Study F3Z-MC-IOQV (IOQV) is a 12-week, multicenter, single-arm, outpatient, exploratory 
study with 2 study periods in subjects with T1D or T2D, respectively, using an investigational 
reusable insulin injection pen and a commercially available CGM device.  Subjects participating 
in the study will follow an appropriate prescribed bolus insulin regimen suitable for their disease 
state using insulin lispro 100 units/mL injected via the reusable insulin injection pen.  During the 
study, subjects will have their glucose monitored via a commercially available CGM device, 
which will be blinded during Study Period 1 and unblinded during Study Period 2.  The main 
purpose of the study is to estimate missed bolus insulin doses in subjects with T1D or T2D.   
Treatment Arm and Duration:   
Study IOQV is a 12-week study with a single treatment arm.  All subjects will administer insulin 
lispro U-100 (100 units/mL) using the investigational reusable insulin injection pen.  All subjects 
will use a commercially available CGM device during the study. 
Number of Subjects:   
Screened:  80 subjects 
Enrolled:  68 subjects 
Completed:  50 subjects 
Statistical Analysis:  
The primary objective of Study IOQV is to objectively measure missed bolus doses in subjects 
with T1D or T2D with blinded CGM.  The primary endpoint is the average number of days per 
month with a missed bolus dose, which will be estimated along with the 95% confidence 
interval.  Secondary analyses will estimate the average number of days per month with a missed 
bolus dose with unblinded CGM, the percent time in glucose range, the percent of missed bolus 
doses, and the missed and suboptimal bolus dose (MSBD) by blinded and unblinded CGM.  
Exploratory analyses will evaluate the correlation between MSBD and CGM alert settings; 
graphically explore subject characteristics associated with short-term glycemic control; estimate 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 10 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
the average number of days per month with a missed bolus dose by type of diabetes (T1D, T2D) 
and CGM (blinded, unblinded). 
Given the exploratory nature of Study IOQV, the analyses will be primarily descriptive.  These 
will include mean, standard deviation, minimum, median, and maximum for continuous 
variables, and frequency and percentage for categorical variables.   

F3Z-MC-IOQV(a) Clinical Protocol 
Page 11 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
2. Schedule of Activities 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 12 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
Table IOQV.1. 
Schedule of Activities 
 
Study Period 1 
Blinded CGM 
Study Period 2 
Unblinded CGM 
 
 
Procedure 
Weeks from Enrollment 
Screening/ 
Enrollment 
V1 
0W 
V2 
3W 
V3 
6W 
V4 
9W 
End of Study 
V5 
12W 
Early 
D/C 
Notes 
Visit Window 
N/A 
3D 
3D 
3D 
3D 
N/A 
Allowable deviation +/- days or 
weeks from scheduled visit. 
Office or home visit 
X 
X 
X 
X 
X 
X 
 
Informed consent 
X 
 
 
 
 
 
 
Inclusion and exclusion criteria 
X 
 
 
 
 
 
 
Demography 
X 
 
 
 
 
 
 
Height and weight 
X 
 
 
 
 
 
 
Medical history 
X 
 
 
 
 
 
 
Current medical conditions 
X 
 
 
 
 
 
Including baseline diabetes disease 
characteristics 
Pregnancy test 
X 
 
 
 
 
 
 
Prescribed insulin regimen 
X 
 
 
 
 
 
Currently prescribed basal and bolus 
insulin regimen 
Concomitant medication review 
X 
X 
X 
X 
X 
X 
 
Enrollment 
X 
 
 
 
 
 
 
HbA1c blood draw a 
X 
 
X 
 
X 
X 
 
Pen dispensing 
X 
 
 
 
 
 
Record pen identification for 
dispensed pens 
Pen training and start pen 
X 
 
 
 
 
 
 
Confirm pen operation 
 
X 
X 
X 
X 
 
 
Pen collection/return 
 
 
 
 
X 
X 
 
CGM and glucose meter training 
X 
 
 
 
 
 
 
CGM and pen data download 
 
X 
X 
X 
X 
X 
 
Adjust CGM alert settings 
 
 
 
X 
 
 
 
Hypoglycemic Confidence Scale 
X 
 
X 
 
X 
X 
 
Adult Low Blood Sugar Survey 
X 
 
X 
 
X 
X 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 13 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Study Period 1 
Blinded CGM 
Study Period 2 
Unblinded CGM 
 
 
The Big Five Inventory 
X 
 
 
 
 
 
 
Health Problem Solving Scale 
X 
 
X 
 
X 
X 
 
Pictorial Representation of Illness and Self Measure 
X 
 
X 
 
X 
X 
 
General Life Stress Scale 
X 
 
X 
 
X 
X 
 
AE and SAE review 
 
X 
X 
X 
X 
X 
 
Product complaint review 
 
X 
X 
X 
X 
X 
 
Abbreviations:  AE = adverse event; CGM = continuous glucose monitoring; D = days; D/C = discontinuation; HbA1c = glycated hemoglobin; N/A = not 
applicable; SAE = serious adverse event; V = visit; W = week. 
a HbA1c testing will be performed by local laboratories. 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 14 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
3. Introduction 
3.1. Study Rationale 
Current diabetes management using basal/bolus insulin regimens requires a high level of patient 
engagement.  One-third of patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) reported 
insulin omission/nonadherence at least once in the past month.  Of those patients, there was an 
average of 3.3 days per month of insulin omission/nonadherence (Peyrot et al. 2012).  Patients 
often cite being too busy, fear of hypoglycemia, and concerns about weight gain as reasons for 
missing doses (Peyrot et al. 2012).  Downloaded dosage data from insulin pump users indicated 
that 65% of pump-using children/adolescents with T1D missed 1 or more mealtime insulin bolus 
doses per week, with an association between missed bolus doses and glycated hemoglobin 
(HbA1c) results (Burdick et al. 2004).  Prior to the development of insulin injection pens that 
track dose data, missed dosage data for multiple daily injection users was obtained by patient 
survey results only.  The investigational reusable insulin injection pen (hereafter referred to as 
“pen”) affords the opportunity to objectively gather omitted or suboptimal insulin dose data via 
pen download.  Additionally, the continuous glucose monitoring (CGM) allows an assessment of 
the impact of bolus dosing on short-term glycemic control. 
Study F3Z-MC-IOQV (IOQV) is an exploratory study to objectively estimate the average 
number of days per month subjects have a missed bolus dose in subjects with T1D or T2D with 
blinded CGM.  In addition, the study will explore any differences in missed bolus insulin doses 
by diabetes type, by CGM (blinded, unblinded), and by subject characteristics.  Study IOQV will 
utilize data from the pen to obtain bolus dose data (including amount and time of dose), along 
with blinded and unblinded CGM to assess short-term glycemic control.   
3.2. Background 
Glycemic control is the ultimate goal of any diabetes treatment regimen.  However, many 
subjects with T1D and T2D continue to have poor glycemic control in large part due to lower 
adherence to their prescribed diabetes treatment regimen due to reasons including diabetes 
knowledge, personal-perceived control, diabetes distress, and regimen-related distress, among 
others (Al-Qazaz et al. 2011; Cummings et al. 2014; Gonzalez et al. 2015).  Many previous 
analyses have been performed by survey results and self-reporting.  The pen, CGM, and 
patient-reported outcomes (PRO) data can document insulin dosing and blood glucose, and 
inform behavior concerning insulin dosing.   
3.3. Benefit/Risk Assessment 
More information about the known and expected benefits, risks, serious adverse events (SAEs), 
and reasonably anticipated adverse events (AEs) can be found in the insulin lispro 100 units/mL 
United States Package Insert (USPI), and pen Investigator’s Brochure (IB). 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 15 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
4. Objectives and Endpoints 
Table IOQV.2 shows the objectives and endpoints of the study. 
Table IOQV.2. 
Objectives and Endpoints 
Objectives 
Endpoint(s) 
Primary 
• To objectively estimate the average number of days per 
month with a missed bolus dose in subjects with type 1 or 
type 2 diabetes with blinded CGM 
 
• The average number of days per month 
with a missed bolus dose 
Secondary 
• To estimate the average number of days per month with a 
missed bolus dose in subjects with type 1 or type 2 
diabetes with unblinded CGM 
• To estimate the percent time-in-range in subjects with type 
1 or type 2 diabetes with 
o 
Blinded CGM  
o 
Unblinded CGM 
• To estimate the percent of missed bolus doses in subjects 
with type 1 or type 2 diabetes with  
o 
Blinded CGM 
o 
Unblinded CGM 
• To estimate the average number of missed bolus doses per 
day in subjects with type 1 or type 2 diabetes with 
o 
Blinded CGM 
o 
Unblinded CGM 
• To estimate the Missed and Suboptimal Bolus Dose 
(MSBD) in subjects with type 1 or type 2 diabetes with  
o 
Blinded CGM  
o 
Unblinded CGM 
 
• The average number of days per month 
with a missed bolus dose 
  
• Percent time-in-range (glucose >70 and 
≤180 mg/dL) 
 
• Percent of missed bolus doses per month 
 
 
 
• 
Average number of missed bolus doses 
per day 
 
 
• 
The average number of MSBD events per 
month 
Exploratory 
• To assess the association between MSBD rate and CGM 
alert settings 
• To evaluate characteristics associated with short-term 
glycemic control in subjects with type 1 or type 2 diabetes  
• To estimate the average number of days per month with a 
missed bolus dose in subjects with type 1 diabetes with  
o 
Blinded CGM  
o 
Unblinded CGM 
• To estimate the average number of days per month with a 
missed bolus dose in subjects with type 2 diabetes with  
o 
Blinded CGM  
o 
Unblinded CGM 
 
• Correlation between MSBD rate and CGM 
alert settings 
• Outcome for each PRO instrument* 
 
• The average number of days per month 
with a missed bolus dose 
 
 
• The average number of days per month 
with a missed bolus dose 
 
Abbreviations:  CGM = continuous glucose monitoring; PRO = patient-reported outcomes. 
* if available for use 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 16 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
5. Study Design 
5.1. Overall Design 
Study IOQV is a 12-week, multicenter, single-arm, outpatient, exploratory study with 2 study 
periods in subjects with T1D or T2D.  Study IOQV will use an investigational pen injector, 
which captures bolus insulin doses, and a commercially available CGM device.  Subjects 
participating in the study will follow an appropriate prescribed insulin regimen suitable for their 
disease state using insulin lispro 100 units/mL injected via the pen.  During the study, subjects 
will have their glucose monitored via the CGM device, which will be blinded during Study 
Period 1 and unblinded during Study Period 2.  In addition, subjects will take PRO evaluations to 
assess potential behaviors related to short-term glycemic control.   
Study governance considerations are described in detail in Appendix 2. 
One study center will be managed by Sponsor designee 
, using telemedicine, mobile 
study nurses, and an electronic application called 
.  Further details about management of 
this study center by 
 are provided in Appendix 4.  
Figure IOQV.1 illustrates the study design.   
 
 
*Pen and Continuous Glucose monitor (CGM) Data collection 
Note:  All visits are in clinic/home 
Figure IOQV.1. 
Illustration of study design for Clinical Protocol F3Z-MC-IOQV. 
5.1.1. Eligibility and Enrollment 
Subjects will be screened at Visit 1 (Week 0) for the assessment of enrollment eligibility.  
Screening assessments are outlined in the Schedule of Activities (SOA) (Table IOQV.1).  
Patients who pass screening assessments based on the inclusion and exclusion criteria set forth in 
Sections 6.1 and 6.2 are eligible to be enrolled in the study.   
CCI
CCI
CCI

F3Z-MC-IOQV(a) Clinical Protocol 
Page 17 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
5.1.2. Study Period 1 
At Visit 1 (Week 0), informed consent will be obtained from each subject.   
Each subject will have a unique subject number assigned, additional eligibility requirements 
evaluated, and laboratory tests will be performed as outlined in the SOA (Table IOQV.1).  After 
confirming eligibility (Visit 1), subjects will be trained on the devices to be used in the study.  
Subjects will be trained by the study site to self-insert the CGM sensor.  If the subject cannot 
self-insert the CGM sensor, the site/study personnel will insert the CGM sensor.  Subjects will be 
blinded to their CGM data.  Subjects will continue their routine blood glucose monitoring as 
needed while using the blinded CGM device.  However, subjects must monitor their blood 
glucose at least twice per day using a provided glucose monitor to calibrate the CGM device 
(Section 7.1.2.1). 
Subjects will begin using the pen to inject insulin lispro 100 units/mL and the blinded CGM 
device as directed at Visit 1 (Week 0) after training.  Subjects entering the study taking 
rapid-acting insulin analog other than insulin lispro 100 units/mL should be switched to insulin 
lispro 100 units/mL using a 1:1 dose conversion unless there are safety concerns as identified by 
the investigator.  Subjects should continue their prestudy basal insulin and concomitant anti-
hyperglycemic therapy and the investigator may adjust the insulin and other diabetes therapy as 
needed.  In addition, the blinded CGM device will record the subject’s glucose during Study 
Period 1 as outlined in the SOA. 
A training checklist for the pen and the CGM device will be provided to investigators to aid in 
subject training.  This training includes, but is not limited to, the operation of the pen and CGM 
device, CGM device calibration, clearing CGM alerts, and other study procedures.  Subjects may 
be retrained on the aforementioned items if deemed appropriate by the study site.  See Section 
7.1.2 for more information regarding the devices used in the study.  
Subjects will be instructed to insert a new sensor weekly and recalibrate the CGM device 
throughout the study.  At Visit 2 (Week 3) and Visit 3 (Week 6), subjects will have their blinded 
CGM data and pen data downloaded by the study site personnel. 
5.1.3. Study Period 2 
Following the completion of Visit 3 (Week 6) assessments, subjects will begin Study Period 2 
and will be unblinded to their CGM data.  
At Visit 4 (Week 9), subjects will have their unblinded CGM data and pen data downloaded by 
the study site personnel and any required adjustments to their CGM device alarms will be 
performed by the study site.  Insulin adjustment recommendations will be provided by the 
investigator and designated staff based on the available glucose and insulin data.  At Visit 5 
(Week 12), subjects will complete their participation in the study, and the site will download all 
of the pen and CGM data since the last visit.  

F3Z-MC-IOQV(a) Clinical Protocol 
Page 18 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
5.2. Number of Subjects 
Approximately 80 patients will be screened to achieve approximately 68 enrolled leading to 
approximately 50 evaluable subjects for Study IOQV.  A minimum of 28 patients and a 
maximum of 40 patients each of T1D and T2D will be enrolled. 
5.3. End of Study Definition 
End of the study is the date of the last visit shown in the SOA (Section 2) for the last subject. 
5.4. Scientific Rationale for Study Design 
This exploratory study objectively estimates bolus doses and their relationship to short-term 
glycemic control and PROs.  The pen allows for objective collection of data that can be assessed 
as missed or suboptimal doses.  Prior to a downloadable pen, other investigators have collected 
bolus data for multiple daily injection users subjectively from patient and/or healthcare 
professional reports.  There is no standard of care or comparator arm because the primary 
objective of this study is to objectively estimate missed bolus doses.  Therefore, the second half 
of Study Period 1 (Visit 2 [Week 3] to Visit 3 [Week 6]) will be used for analyses with blinded 
CGM.  The study duration of 12 weeks (2 parts of 6 weeks each) is adequate based on the 
inclusion criteria of 3 or more bolus doses daily for the assessment of missed bolus doses.  Each 
enrolled subject must be on a mealtime bolus insulin regimen with each individual bolus insulin 
dose being <40 units (Section 6.1).  Adult T1D and T2D populations were chosen to explore 
whether there might be differences based on disease type. 
5.5. Justification for Dose 
The dose of insulin lispro 100 units/mL to be used in the study will be different for each subject 
according to their insulin needs.  Subjects will be instructed to continue their prestudy basal 
insulin and concomitant antihyperglycemic therapy.  The investigator can make basal and bolus 
insulin adjustments as needed.  The prescribed insulin regimen will be determined from the 
subject’s medical records at the start of the study, and any dosage adjustments needed during the 
study shall be documented for analysis (Section 7.4).  Subject’s basal insulin and concomitant 
antihyperglycemic therapy may be adjusted as needed per investigator’s discretion as needed for 
safety (Section 7.7).   

F3Z-MC-IOQV(a) Clinical Protocol 
Page 19 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
6. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted. 
6.1. Inclusion Criteria 
Patients are eligible to participate in the study only if they meet all of the following criteria at 
screening: 
Type of Subject and Disease Characteristics 
[1] Subjects with a T1D or T2D diagnosis: 
i) Mealtime bolus dose insulin (≥3 doses). 
ii) Each individual bolus insulin dose must be <40 units. 
iii) Subjects must be taking a stable insulin dose regimen per the investigator’s 
judgement for the 3 months preceding screening. 
[2] Subjects must be taking a bolus insulin analog (for example insulin lispro [U-
100]/[U-200], insulin aspart, or insulin glulisine).  In addition, the subject 
must be able to switch to insulin lispro U-100 for the duration of the trial per 
the investigator’s judgement, if taking a bolus insulin analog other than insulin 
lispro U-100.  
[3] Subjects must have a HbA1c ≥8.0% in the last 6 months. 
[4] 
Subjects with T1D must be ≥21 to ≤65 years of age at screening.  Subjects with T2D 
must be ≥35 to ≤65 years of age at screening. 
Subject Characteristics 
[5a] Male subjects: 
 
No male contraception required except in compliance with specific local 
government study requirements. 
[5b] Female subjects: 
Women of non-childbearing and childbearing potential. Women of childbearing 
potential are defined as: 
Female subjects as any female who has experienced menarche and who is NOT 
permanently sterile or postmenopausal. Postmenopausal is defined as 12 
consecutive months with no menses without an alternative medical cause.  These 
subjects: 
I. 
Must agree to use 1 highly effective method of contraception, or a 
combination of 2 effective methods of contraception for the entirety of the 
study (Appendix 3) 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 20 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
II. 
Must test negative for pregnancy as indicated by a negative serum or urine 
pregnancy test at screening. 
[6] Subjects with prior CGM/flash glucose monitoring experience must have 
stopped CGM/flash glucose monitoring ≥3 months prior to enrollment.   
[7] Study materials and devices will only be provided in English.  Subjects must 
be comfortable with understanding the English language. 
Informed Consent 
[8] Are able and willing to give signed informed consent. 
6.2. Exclusion Criteria 
Patients will be excluded from study enrollment if they meet any of the following criteria: 
Medical Conditions 
[9] Subjects with known tape/adhesive allergies with CGM sensors. 
[10] Subjects with medical conditions, visual, physical, psychiatric, or cognitive 
impairment(s) that may preclude the ability to participate in the trial per the 
investigator’s discretion. 
[11] Have a documented medical history of or obvious clinical signs or symptoms 
of liver disease, acute or chronic hepatitis, or a history of alanine 
aminotransferase or aspartate aminotransferase levels ≥3 times the upper limit 
of the reference range within the last 6 months before screening. 
[12] Have documented medical history of chronic kidney disease stage 4 and 
higher within the last 6 months before screening or history of renal 
transplantation. 
[13] Have active malignancy. 
[14] Are pregnant or planning to become pregnant. 
[15] Are on or are intending on beginning a weight loss program.  
Prior/Concomitant Therapy 
[16] Subjects with T1D who have taken off-label antihyperglycemic agents within 
3 months prior to screening. 
[17] Have received insulin by continuous subcutaneous insulin infusion in the 
3 months prior to screening. 
[18] Subjects taking opioid medications at screening for medically invalid reasons 
or at doses considered excessive for the treated condition per the 
investigator’s discretion. 
[19] Subjects on routine use of acetaminophen at screening per the investigator’s 
judgement.  

F3Z-MC-IOQV(a) Clinical Protocol 
Page 21 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
[20] Currently undergoing systemic treatment with: 
• Immunosuppressive medication. 
• Chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy 
(excluding topical and inhaled preparations) or have received such therapy 
within 2 weeks immediately before Visit 1 (Week 0). 
Prior/Concurrent Clinical Trial Experience 
[21] Are currently enrolled in any other clinical study involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this study. 
[22] Have participated, within the last 30 days, in a clinical study involving an 
investigational product.  If the previous investigational product has a long 
half-life, 5 half-lives or 30 days (whichever is longer) should have passed. 
[23] Have previously completed or withdrawn from this study.   
Other Exclusions 
[24] Are investigator site personnel directly affiliated with this study and/or their 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally adopted. 
[25] Are Lilly employees or are employees of any third party involved in the study 
who require exclusion of their employees. 
[26] Are unwilling or unable to comply with the use of a data collection device to 
directly record data from the subject. 
6.3. Lifestyle Restrictions 
Subjects must have a stable lifestyle with no changes to dietary or exercise habits during the 
course of the study. 
6.4. Screen Failures 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.   

F3Z-MC-IOQV(a) Clinical Protocol 
Page 22 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
7. Treatments 
7.1. Treatments Administered 
This study involves the treatment of subjects with diabetes with marketed insulin lispro 
(100 units/mL) administered by the pen.  Table IOQV.3 shows the treatment regimens.  Subjects 
will continue their pre-study concomitant anti-hyperglycemic medication and basal insulin 
therapies during the study. 
Table IOQV.3. 
Treatment Regimens 
Study Period 1 
Study Period 2 
Insulin lispro doses as prescribed delivered via the pen. 
CGM data blinded. 
Insulin lispro doses as prescribed delivered via the pen. 
CGM data unblinded. 
Abbreviation:  CGM = continuous glucose monitoring. 
 
The investigator or his/her designee is responsible for the following: 
• explaining the correct use of the pen, the commercially available CGM device, 
and the glucometer to the subject or the subject’s legal representative. 
• maintaining accurate records of all pens, medication vouchers/pharmacy cards, 
and device dispensing and collection. 
• at the end of the study, all pens, the CGM device, and glucose meter must be 
returned to Lilly or its designee.   
7.1.1. Packaging and Labeling 
Clinical study materials will be labeled according to United States (US) regulatory requirements. 
7.1.2. Medical Devices 
The medical device provided for use in the study is the investigational reusable insulin injection 
pen, which collects dose administration information.  The other devices provided for use during 
the study are a commercially available CGM device (
 and a glucose meter.   
As each subject completes the study, accountability will be completed and the returned items 
will be stored as instructed.  Detailed information about this process will be available as part of 
site’s working manual. 
7.1.2.1. Continuous Glucose Monitoring  
The commercially available CGM device that will be used during the study is the 
 
, which consists of a glucose sensor, data transmitter, and data receiver that assesses 
interstitial glucose readings every 5 minutes.  The 
 can be blinded or 
unblinded.  The 
 should be calibrated at least once every 12 hours by a finger 
stick blood glucose reading from the provided glucose meter.  The calibration of the 
 
 should be done during both study periods when the CGM system is in use. 
CCI
CCI
CCI
CCI
CCI

F3Z-MC-IOQV(a) Clinical Protocol 
Page 23 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
7.1.2.2. Investigational Reusable Insulin Injection Pen 
The insulin injection device to be used in Study IOQV is an investigational reusable pen injector 
for the delivery of a subcutaneous injection of insulin using the standard Lilly 3 mL Humalog 
U-100 glass cartridges.  The pen is a variable dose device for use in patients with T1D or T2D.  
The pen dials in 1-unit increments with a 60 unit maximum dose, and requires a new pen needle 
for each injection.  The pen contains an organic light-emitting diode display and memory 
function which allows for insufficient remaining dose detection (while displaying the remaining 
partial dose), last dose display (time since last dose and units delivered), a full dose history in 
memory, and “Injection Complete” prompt.  The pen contains electronics with the capability to 
store dosage data and download the data by the study site personnel.  Due to the investigational 
nature of the reusable insulin injection pen, this study is also following 21 CFR 812 guidelines 
for investigational devices.  
7.2. Method of Treatment Assignment 
Subjects who meet all inclusion/exclusion criteria (Sections 6.1 and 6.2) will be enrolled into the 
study at Visit 1 (Week 0).  This study is an open-label, single-arm study for which all subjects 
are receiving insulin lispro 100 units/mL.   
7.2.1. Selection and Timing of Doses 
The doses will be administered according to the subject’s usual practices.  The actual dose and 
time of all dose administrations will be recorded by the pen and downloaded by study site 
personnel.  Subjects will continue their prestudy basal insulin and concomitant 
antihyperglycemic therapy and the investigator may make insulin dose adjustments as indicated.   
7.3. Blinding 
This is an open-label study.  Subjects and study personnel will not be blinded to insulin lispro 
100 units/mL administered via the pen.  Subjects will not have access to their historical bolus 
dosing data from the pen with the exception of the display indicating the duration since their last 
bolus dose.  Additionally during Study Period 1, subjects will be blinded to their CGM readings 
(Figure IOQV.1).  Subjects and the study personnel will be unblinded to the subject’s CGM data 
during Study Period 2. 
7.4. Dosage Modification 
Insulin dosage modifications are not required during the study but may be indicated.  Therefore, 
insulin adjustments are allowed based on the investigator’s medical judgement using the 
available glucose and insulin data.  Subjects who are adjusted to a single bolus insulin dose of 
>40 units per injection will be discontinued from the study.   
7.5. Preparation/Handling/Storage/Accountability 
The investigator or his/her designee is responsible for the following: 
• Device training on the pen, CGM system, and glucometer. 
• Completion of the checklist for all device training. 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 24 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
• Ensuring that only subjects receive study treatment vouchers.  
• The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study treatment voucher accountability, 
reconciliation, and record maintenance (such as receipt, reconciliation, and final 
disposition records). 
7.6. Treatment Compliance 
Compliance of pen utilization will be assessed at each visit.  To avoid missing data, the pen and 
CGM data will be downloaded at predetermined time points described in the SOA.   
7.7. Concomitant Therapy 
Other concomitant therapies that are part of routine care are allowed and can be used during the 
study at the investigator’s discretion.  A list of medications not allowed will be provided 
separately.  Any change in the list of medications not allowed will be communicated to 
investigators, and will not constitute a protocol amendment. 
A subject’s concomitant antihyperglycemic therapy may be adjusted as needed per investigator’s 
discretion for safety.  
7.8. Treatment after the End of the Study 
7.8.1. Treatment after Study Completion 
The pen or insulin lispro will not be made available to study participants after conclusion of the 
study.  Subjects will resume their standard insulin therapy at the completion of the study. 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 25 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
8. Discontinuation Criteria 
8.1. Discontinuation from Study Treatment 
8.1.1. Permanent Discontinuation from Study Treatment 
Discontinuation from study treatment (i.e., the pen) for a total of >3 days would lead to 
permanent discontinuation from study treatment as the purpose of the study is to collect data on 
bolus dosing.  If a subject is permanently discontinued from study treatment, they will also be 
discontinued from the study. 
8.1.2. Temporary Discontinuation from Study Treatment 
Subjects may temporarily discontinue study treatment for a total of ≤3 days due to temporary 
hospitalization, medical procedure, loss of the pen, or per the investigator’s judgement.   
8.1.3. Discontinuation of Inadvertently Enrolled Subjects 
If the sponsor or investigator identifies a subject who did not meet enrollment criteria and was 
inadvertently enrolled, then the subject should be permanently discontinued from study 
treatment.  Safety follow-up is as outlined in the SOA (Table IOQV.1), Section 9.2 (Adverse 
Events), and Section 9.4 (Safety) of the protocol. 
8.2. Discontinuation from the Study 
Subjects will be discontinued in the following circumstances:   
• if the subject becomes pregnant during the study as determined by a serum or 
urine pregnancy test performed at the investigator’s suspicion of possible 
pregnancy. 
• enrollment in any other clinical study involving an investigational product or 
enrollment in any other type of medical research as judged by the sponsor not 
to be scientifically or medically compatible with this study. 
• for medical, safety, regulatory, or other reasons consistent with applicable 
laws, regulations, and good clinical practice (GCP). 
• subjects who are adjusted to a single bolus insulin dose of >40 units per 
injection. 
• if the subject discontinues study treatment for a total of >3 days. 
• Investigator Decision 
o the investigator decides that the subject should be discontinued from the 
study. 
o if the investigator deems it necessary to stop insulin lispro treatment. 
• Subject Decision 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 26 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
o the subject or the subject’s designee requests to be withdrawn from the 
study. 
• Sponsor Decision 
o if the subject loses or otherwise renders the pen (and its replacement pen) 
inoperable, the sponsor may discontinue that subject from the study.  
o the sponsor decides to stop the study. 
Subjects discontinuing from the study prematurely for any reason should complete AE and other 
safety follow-up per Section 2 (SOA), Section 9.2 (Adverse Events), and Section 9.4 (Safety) of 
this protocol. 
8.3. Lost to Follow-Up 
A subject will be considered lost to follow-up if he or she repeatedly fails to attend scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site. 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 27 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
9. Study Assessments and Procedures 
Section 2 lists the SOA, with the study procedures and their timing (including tolerance limits for 
timing). 
9.1. Efficacy Assessments 
9.1.1. Primary Efficacy Assessments 
The primary efficacy assessment objectively estimates the average number of days per month 
with a missed bolus dose in subjects with type 1 or type 2 diabetes using blinded CGM 
measurements and the pen.  Missed bolus doses will be determined by the glucose excursion as 
measured by the CGM. 
• 
A subject is counted as missing 1 injection, if the subject does not have any injection record 
during the 1-hour interval prior to a glucose excursion (≥80 mg/dL) in the 2-hour 
postprandial interval.   
Example:  In the theoretical CGM profile (Figure IOQV.2), 2 glucose excursions 
≥80 mg/dL within a 2-hour interval are observed:   
o 
nadir at 11 am and peak at 12 pm,  
o 
nadir at 1:30 pm and high at 2:15 pm.   
If the associated insulin pen data show no injection between 10 am and 11 am and 1 
injection between 12:30 pm and 1:30 pm, then the subject has 1 missed injection 
corresponding to the 11 am-12 pm glucose excursion. 
 
Figure IOQV.2. 
Example of a missed injection using a CGM profile. 
9.1.2. Secondary Assessments 
Study IOQV will have 5 secondary efficacy measures as described in Table IOQV.2.  The first 
secondary objective is similar to the primary objective (Section 9.1.1) except that the information 
to be analyzed will be using unblinded CGM data.  Missed bolus doses will be determined by the 
glucose excursion as measured by the unblinded CGM.   

F3Z-MC-IOQV(a) Clinical Protocol 
Page 28 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Study IOQV will also estimate the percent time-in-range in subjects with T1D or T2D using 
blinded and unblinded CGM data.  The glucose range for this analysis is >70 and ≤180 mg/dL.  
In addition, the percent of missed bolus doses per month and the average number of missed bolus 
doses per day will be estimated in subjects with T1D and T2D on both the blinded and unblinded 
CGM.  The final secondary objective will estimate the average number of MSBD events per 
month in subjects with T1D or T2D using data obtained from the blinded and unblinded CGM 
phases of the study. 
9.1.3. Exploratory Assessments 
Study IOQV will possibly explore 6 different PRO evaluations that the subject will perform at 
time points outlined in the SOA (Table IOQV.1).  These PRO evaluations are the Hypoglycemic 
Confidence Scale (HCS), Adult Low Blood Sugar Survey (ALBSS), the Big Five Inventory 
(BFI), Health Problem Solving Scale (HPSS), the Pictorial Representation of Illness and Self 
Measure Revised II (PRISM R II), and the General Life Stress Scale (GLSS).  The details of 
each PRO evaluation are listed in the following sections. 
9.1.3.1. Hypoglycemic Confidence Scale 
The HCS examines the degree to which people with diabetes feel able, secure, and comfortable 
regarding their ability to stay safe from hypoglycemic-related problems (Polonsky et al. 2017).  
The HCS has been validated for use in adults with T1D and insulin-using T2D patients.  This 
evaluation uses the Likert scale with ratings of not confident at all, a little confident, moderately 
confident, and very confident to rate a subject’s response to 9 items during the evaluation (8 
items for subjects without a partner and 9 for subjects with a partner).  Each item will receive a 
score from 1 to 4 based on the subject’s response.  Scores are calculated as the sum total item 
score divided by the number of items completed (8 items for participants without a partner and 
9 for participants with a partner).  Higher scores mean greater confidence (Polonsky et al. 2017).   
9.1.3.2. Adult Low Blood Sugar Survey 
The ALBSS is an evaluation of the fear of hypoglycemia derived from the widely used and 
validated ALBSS.  This evaluation uses the Likert scale of 0 (“never”) to 4 (“almost always”) to 
rate 11 items (Behavior domain with 5 items; Worry domain with 6 items).  A higher total score 
means greater fear (Cox et al. 1987; Grabman et al. 2017). 
9.1.3.3. The Big Five Inventory 
The BFI is 44-item inventory that measures an individual on the Big Five Factors (dimensions) 
of personality, Extraversion versus introversion (8 items), Agreeableness versus antagonism 
(9 items), Conscientiousness versus lack of direction (9 items), Neuroticism versus emotional 
stability (8 items), and Openness versus closedness to experience (10 items).  Identifying a 
patient’s thinking, feeling, and behaving may help clinicians avoid suggesting solutions that will 
not work for that patient’s personality type (APA WWW).  The evaluation uses a Likert scale of 
(1) disagree strongly, (2) disagree a little, (3) neither agree nor disagree, (4) agree a little, and 
(5) agree strongly. (Goldberg 1981). 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 29 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
9.1.3.4. Health Problem Solving Scale 
Patient problem-solving has been shown to be a predictor of coping and health behaviors and 
was related to improved outcomes in diabetes (Glasgow et al. 2007).  The HPSS can be used to 
“identify patients who may be most in need of problem-solving interventions as part of patient 
education and disease self-management training” (Hill-Briggs et al. 2007).  It is of interest to 
evaluate a person’s problem-solving abilities in association with the number of and/or frequency 
of missed mealtime insulin doses.   
The scale is a set of 50 items that the subject rates using a 5-point Likert scale ranging from “not 
at all true of me” (0 points) to “extremely true of me” (4 points).  Seven subscale scores are 
calculated by summing scores for each item in the respective subscale.  The HPSS total score is 
derived by using the sums of the subscale averages, with reverse scoring of the negative 
subscales.  Higher subscale scores indicate more of a problem-solving characteristic.  A higher 
total HPSS score indicates a more effective health-related problem-solving skill (Hill-Briggs et 
al. 2007). 
9.1.3.5. Pictorial Representation of Illness and Self Measure Revised II 
The PRISM R II is a visual representation of burden of suffering from diabetes in a patient’s life.  
This evaluation allows for discussion on the importance of diabetes in the patient’s life that may 
provide insight into any barriers to successful diabetes management.   
The PRISM R II consists of a large white paper circle, representing the subjects’ life, with a 
yellow paper circle placed in the middle and in front/on top of the white circle, representing the 
respondents’ self.  Three differently sized red paper circles represent the respondents’ diabetes.  
The diabetes circles are respectively smaller than, equal to, and larger than the self circle.  
Subjects are given the following written instruction:  “The white circle represents your current 
life and the yellow circle represents you.  The three red circles represent your diabetes.  Select 
from the three red circles the one that, in your view, represents your diabetes most accurately.  
Place the circle into your life.  Locate the circle at the place that the diabetes occupies in your 
life.  You can place the circle anywhere in your life, also entirely or partially on top of your self.”  
Two measures are extracted from the PRISM R II, Self Illness Separation where greater 
distances correspond to less burden and the Illness Perception Measure ranging from 1 to 3 with 
1 representing the smallest disk (Klis et al. 2008).  
9.1.3.6. General Life Stress Scale 
The GLSS assesses the degree of stress an individual is currently experiencing in 5 general areas 
of life (finance, work, their romantic relationship, family, and health problems—modified to 
inquire about health problems other than diabetes) within 6 items, with response options ranging 
from 0 (“none”) to 4 (“a great deal”).  The total score is calculated, with higher scores reflecting 
greater overall life stress (Hessler et al. 2016). 
9.1.4. Appropriateness of Assessments 
The objective collection of bolus dosing data using the pen will help to better understand actual 
dosing behavior.  The use of the commercially available CGM device will provide an assessment 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 30 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
of blood glucose control to better understand the relationship with bolus dosing.  The PROs will 
allow a better understanding of patient’s behavior and the relationship with bolus dosing.  
9.2. Adverse Events and Device Complaints 
Investigators are responsible for monitoring the safety of subjects who have entered this study 
and for alerting Lilly or its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the subject.  The investigator is responsible for the 
appropriate medical care of subjects during the study.  Investigators must document their review 
of each laboratory safety report. 
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the investigational 
product or the study, or that caused the subject to discontinue the investigational product before 
completing the study.  The subject should be followed until the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency of follow-up 
evaluations of the AE is left to the discretion of the investigator.  Lack of drug effect is not an 
AE in clinical studies. 
Hypoglycemia, as outlined in Section 9.2.1.1, should be considered an AE when reported by the 
study participant. 
After the informed consent form (ICF) is signed, study site personnel will record via the case 
report form (CRF) the occurrence and nature of each subject’s preexisting conditions, including 
clinically significant signs and symptoms of the disease under treatment in the study.  In 
addition, site personnel will record any change in the condition(s) and any new conditions as 
AEs.  Investigators should record their assessment of the potential relatedness of each AE to 
protocol procedure, investigational device, or investigational product, via CRF.  
The investigator will interpret and document whether or not an AE has a reasonable possibility 
of being related to study treatment, investigational study device, or a study procedure, taking into 
account the disease, concomitant treatment, or pathologies.   
A “reasonable possibility” means that there is a cause and effect relationship between the 
investigational product, investigational study device and/or study procedure, and the AE. 
The investigator answers yes/no when making this assessment.  If relatedness to study device is 
“yes”, a product complaint will also need to be submitted. 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the study. 
If a subject’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via CRF, clarifying if possible, the circumstances leading 
to any dosage modifications, or discontinuations of treatment.   
9.2.1. Serious Adverse Events 
An SAE is any AE from this study that results in one of the following outcomes: 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 31 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
• death 
• initial or prolonged subject hospitalization 
• a life-threatening experience (i.e., immediate risk of dying) 
• persistent or significant disability/incapacity 
• congenital anomaly/birth defect 
• important medical events that may not be immediately life threatening or result in 
death or hospitalization but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed in the definition above.  
Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in subject hospitalization, or the development of 
drug dependency or drug abuse. 
• when a condition related to the pen necessitates medical or surgical intervention 
to preclude either permanent impairment of a body function or permanent damage 
to a body structure, the serious outcome of “required intervention” will be 
assigned. 
• severe hypoglycemia 
All AEs occurring after signing the ICF are recorded in the CRF and assessed for serious criteria.  
The SAE reporting to the sponsor begins after the subject has signed the ICF and has received 
investigational product.  However, if an SAE occurs after signing the ICF, but prior to receiving 
investigational product, the SAE should be reported to the sponsor as per SAE reporting 
requirements and timelines (see Section 9.2) if it is considered reasonably possibly related to 
study procedure. 
Study site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator 
awareness of the event via a sponsor-approved method.  If alerts are issued via telephone, they 
are to be immediately followed with official notification on study-specific SAE forms.  This 
24-hour notification requirement refers to the initial SAE information and all follow-up SAE 
information.  Subjects with a serious hepatic AE should have additional data collected using the 
CRF. 
Pregnancy (during maternal or paternal exposure to investigational product) does not meet the 
definition of an AE.  However, to fulfill regulatory requirements, any pregnancy should be 
reported following the SAE process to collect data on the outcome for both mother and fetus. 
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study (the subject disposition CRF has been completed).  
However, if the investigator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study, and he/she considers the event reasonably possibly related to the 
study treatment or study participation, the investigator must promptly notify Lilly. 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 32 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
9.2.1.1. Severe Hypoglycemia 
Severe hypoglycemia is defined as an event accompanied by neuroglycopenic symptoms that 
result in cognitive impairment such that the patient requires assistance of another person to 
actively administer carbohydrate, glucagon, or perform other resuscitative actions.  During these 
episodes, the patient has an altered mental status, and cannot assist in their care, is semiconscious 
or unconscious, or experienced coma with or without seizures, and may require parenteral 
therapy.  Plasma glucose measurements may not be available during such an event, but 
neurological recovery attributable to the restoration of self-monitored blood glucose (SMBG) 
concentration to normal is considered sufficient evidence that the event was induced by a low 
SMBG concentration (≤70 mg/dL). 
Documented symptomatic hypoglycemia is defined as an event that is accompanied by 
signs/symptoms of hypoglycemia, and is accompanied by a measured SMBG concentration of 
≤70 mg/dL. 
9.2.1.2. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the USPI and that the investigator identifies as related to investigational product(s) or 
procedure.  Lilly has procedures that will be followed for the identification, recording, and 
expedited reporting of SUSARs that are consistent with global regulations and the associated 
detailed guidances. 
9.2.2. Adverse Device Effects 
The investigator is responsible for sending to the sponsor within 24 hours any and/or associated 
product complaints involving a device malfunction of the pen, using the AE process and 
associated complaint report.  Lilly will investigate all (S)AEs and associated complaints to 
determine the extent to which the event was caused by, or associated with, the investigational 
device.  
Lilly will follow procedures consistent with US regulations to confirm and handle any 
unanticipated adverse device effects (UADEs), and will inform the Food and Drug 
Administration of confirmed UADEs following an investigation of the event.  Within 10 working 
days of learning of the event, the principal investigator will then report evaluation results for any 
UADE to all reviewing Institutional Review Boards.   
All UADEs will be summarized in the final study report. 
9.2.3. Complaint Handling 
Lilly collects product complaints on investigational products and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product improvements. 
Specifically, a product complaint is an expressed (written or verbal) statement regarding a 
deficiency in the expected performance of the device (e.g., did not work as intended; 
malfunctioned; difficult to use).  A product complaint may occur independently from an AE, or 
along with an AE.  A product complaint may also occur independently of a device malfunction.  

F3Z-MC-IOQV(a) Clinical Protocol 
Page 33 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
The site is responsible for collecting all product complaints and reporting these to the sponsor via 
the provided product complaint form template.  Device malfunctions on any Lilly product 
(e.g., failure of the investigational device to perform as intended) will be reported to the sponsor, 
irrespective of whether associated with an AE.  
The investigator must instruct subjects to contact the clinical site as soon as possible if he or she 
has a complaint or problem with the product, investigational reusable insulin injection pen, or the 
commercially available CGM device so that the situation can be assessed. 
All investigational reusable devices associated with complaints must be returned to the sponsor 
for evaluation. 
9.3. Treatment of Overdose 
Refer to product labeling for insulin lispro 100 units/mL (USPI). 
9.4. Safety 
9.4.1. Laboratory Tests 
For each subject, the local laboratory test for HbA1c should be conducted according to the SOA 
(Table IOQV.1).  A pregnancy test may be performed at the investigator’s discretion if there is 
suspicion of possible pregnancy. 
9.4.2. Safety Monitoring 
Lilly will periodically review evolving aggregate safety data within the study by appropriate 
methods. 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 34 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
10. Statistical Considerations 
10.1. Sample Size Determination 
Approximately 68 subjects may be entered (i.e., signed informed consent) in order that 50 
subjects complete the study.  Subjects who are entered but not administered treatment may be 
replaced to ensure that enough subjects may complete the study.  Assuming a screen fail rate of 
15%, the expected number of subjects to be screened is 80. Up to 15 subjects may be enrolled at 
each investigator site.  
A sample size of 50 completers (approximately 25 subjects with T1D and 25 subjects with T2D) 
is considered sufficient for this exploratory study. 
10.2. Populations for Analyses 
For purposes of analysis, the following analysis sets are defined: 
Table IOQV.4. 
Analysis Sets 
Analysis Set 
Description 
Entered 
All participants who signed informed consent 
Evaluable 
All enrolled subjects with ≥2-week use of unblinded CGM 
Safety 
All enrolled subjects with any CGM or pen usage 
Abbreviation:  CGM = continuous glucose monitoring. 
10.3. Statistical Analyses 
10.3.1. General Statistical Considerations 
Statistical analysis of this study will be the responsibility of Lilly or its designee. 
Efficacy analyses will be conducted on the evaluable analysis set and safety analyses on the 
safety analysis set defined in Table IOQV.4. 
Given the exploratory nature of the study, the analyses will be primarily descriptive, using 
descriptive statistics (mean, standard deviation [SD], minimum, median, and maximum for 
continuous variables; frequency and percentage for categorical variables) or graphs (e.g., scatter 
plot).   
Missed bolus doses and glucose time-in-range will be calculated for Weeks 3-6 for Study 
Period 1 (blinded CGM) and Weeks 9-12 for Study Period 2 (unblinded CGM). 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report (CSR).  Additional exploratory analyses of the data will be conducted 
as deemed appropriate. 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 35 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
10.3.1.1. Treatment Group Comparability 
10.3.1.2. Subject Disposition 
The primary reasons for discontinuation will be summarized by study period and subject 
allocation will be summarized by investigative site for the entered analysis set. 
10.3.1.3. Subject Characteristics 
Baseline characteristics will be summarized for the entered analysis set and the evaluable 
analysis set. 
10.3.1.4. Treatment Compliance 
Amount of useable data from the CGM device and pen will be summarized for the evaluable 
analysis set. 
10.3.2. Efficacy Analyses 
10.3.2.1. Primary Analyses 
The average number of days per month with a missed bolus dose during the last 3 weeks of 
Study Period 1 will be summarized.  The 3 weeks of data will be adjusted to a 1-month interval, 
and a 95% confidence interval will be calculated. 
10.3.2.2. Secondary Analyses 
The percent glucose time-in-range (>70 and ≤180 mg/dL) will be calculated and summarized for 
Study Period 1 and Study Period 2.  The number of missed bolus doses (average number of 
missed bolus doses per day) as well as the percent of missed bolus doses (adjusted to a 1-month 
interval) will be summarized by Study Period 1 and Study Period 2.  The MSBD will be 
summarized by Study Period 1 and Study Period 2.  
10.3.3. Safety Analyses 
Adverse events including discontinuations due to AEs and SAEs will be summarized.   
10.3.4. Other Analyses 
Patient reported outcomes rated on the Likert scale will be summarized using frequency and 
percentage.  Domain or total scores will be summarized using:  n, mean, SD, minimum, median, 
maximum at the times outlined in the SOA (Table IOQV.1).   
In addition, bolus dose, basal insulin dose information, and exposure will be summarized.   
10.3.4.1. Subgroup Analyses 
The average number of missed bolus doses per month will be summarized for the following 
baseline subgroups:   
• Glucose time-in-range (≤median vs. >median); 
• HbA1c (≤9.0% vs. >9.0%); 
• Duration of diabetes (≤median vs. >median); 
• Prior CGM experience (yes vs. no). 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 36 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
10.3.5. Interim Analyses 
No interim analyses are planned for this study.   

F3Z-MC-IOQV(a) Clinical Protocol 
Page 37 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
11. References 
Al-Qazaz HKh, Sulaiman SA, Hassali MA, Shafie AA, Sundram S, Al-Nuri R, Saleem F. 
Diabetes knowledge, medication adherence and glycemic control among patients with type 2 
diabetes. Int J Clin Pharm. 2011;33(6):1028-1035.  
[APA] American Psychological Association. Personality. Available at 
http://www.apa.org/topics/personality/. Accessed on 25 July 2017. 
Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, Klingensmith GJ. 
Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin 
pump therapy. Pediatrics. 2004;113(3 Pt 1):e221-224. 
Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: 
quantification, validation, and utilization. Diabetes Care. 1987;10(5):617-621. 
Cummings DM, Lutes L, Littlewood K, DiNatale E, Hambidge B, Schulman K, Morisky DE. 
Regimen-Related Distress, Medication Adherence, and Glycemic Control in Rural African 
American Women With Type 2 Diabetes Mellitus. Ann Pharmacother. 2014;48(8):970-977. 
Glasgow RE, Fisher L, Skaff M, Mullan J, Toobert DJ. Problem solving and diabetes self-
management: investigation in a large, multiracial sample. Diabetes Care. 2007;30(1):33-37. 
Goldberg LR. Language and individual differences: The search for universals in personality 
lexicons. Review of Personality and Social Psychology. 1981;2:141-165. 
Gonzalez JS, Shreck E, Psaros C, Safren SA. Distress and type 2 diabetes-treatment adherence: 
A mediating role for perceived control. Health Psychol. 2015;34(5):505-513. 
Grabman J, Vajda Bailey K, Schmidt K, Cariou B, Vaur L, Madani S, Cox D, Gonder-Frederick 
L. An empirically derived short form of the Hypoglycaemia Fear Survey II. Diabet Med. 
2017;34(4):500-504. 
Hessler D, Fisher L, Polonsky W, Johnson N. Understanding the Areas and Correlates of 
Diabetes-Related Distress in Parents of Teens With Type 1 Diabetes. J Pediatr Psychol. 
2016;41(7):750-758. 
Hill-Briggs F, Gemmell L, Kulkarni B, Klick B, Brancati FL. Associations of patient health-
related problem solving with disease control, emergency department visits, and 
hospitalizations in HIV and diabetes clinic samples. J Gen Intern Med. 2007;22(5):649-654. 
Klis S, Vingerhoets AJ, de Wit M, Zandbelt N, Snoek FJ. Pictorial Representation of Illness and 
Self Measure Revised II (PRISM-RII): a novel method to assess perceived burden of illness in 
diabetes patients. Health Qual Life Outcomes. 2008;6:104. 
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and 
barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy 
study. Diabet Med. 2012;5(29):682-689. 
Polonsky WH, Fisher L, Hessler D, Edelman SV. Investigating Hypoglycemic Confidence in 
Type 1 and Type 2 Diabetes. Diabetes Technol Ther. 2017;19(2):131-136.  
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 38 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 39 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
12. Appendices 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 40 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Appendix 1. 
Abbreviations and Definitions 
Term 
Definition 
AE 
adverse event:  Any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product. 
ALBSS 
Adult Low Blood Sugar Survey 
BFI 
The Big Five Inventory 
CGM 
continuous glucose monitoring 
CIOMS 
Council for International Organizations of Medical Sciences 
complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system. 
compliance 
Adherence to all study-related, good clinical practice (GCP), and applicable regulatory 
requirements. 
CRF 
case report form 
CSR 
clinical study report 
enroll 
The act of assigning a subject to a treatment.  Subjects who are enrolled in the study are 
those who have been assigned to a treatment. 
enter 
Subjects entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives. 
ERB 
ethical review board 
FOIA 
Freedom of Information Act 
GCP 
good clinical practice 
GLSS 
General Life Stress Scale 
HbA1c 
glycated hemoglobin 
HCS 
Hypoglycemic Confidence Scale 
HPSS 
Health Problem Solving Scale 
IB 
Investigator’s Brochure 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 41 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Term 
Definition 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
Informed consent 
A process by which a subject voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the subject’s decision to participate.  Informed consent is documented by 
means of a written, signed and dated informed consent form. 
investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form. 
IOQV 
F3Z-MC-IOQV 
Malfunction 
Any failure of a device to meet its performance specifications or otherwise perform as 
intended.  Performance specifications include all claims made in the labeling for the 
device.  The intended performance of a device refers to the intended use for which the 
device is labeled or marketed. 
MSBD 
missing and suboptimal bolus dose 
PRISM R II 
Pictorial Representation of Illness and Self Measure Revised II 
PRO/ePRO 
patient-reported outcomes/electronic patient-reported outcomes 
SAE 
serious adverse event 
screen 
The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SD 
standard deviation 
SMBG 
self-monitored blood glucose 
SOA 
Schedule of Activities 
SUSARs 
suspected unexpected serious adverse reactions 
T1D 
type 1 diabetes 
T2D 
type 2 diabetes 
UADE 
Unanticipated Adverse Device Effect:  Any serious adverse effect on health or safety or 
any life-threatening problem or death caused by, or associated with, a device, if that 
effect, problem, or death was not previously identified in nature, severity, or degree of 
incidence in the investigational plan or application (including a supplementary plan or 
application), or any other unanticipated serious problem associated with a device that 
relates to the rights, safety, or welfare of subjects. 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 42 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Term 
Definition 
US 
United States 
USPI 
United States Package Insert 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 43 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Appendix 2. 
Study Governance Considerations 
Appendix 2.1. Regulatory and Ethical Considerations, Including the 
Informed Consent Process 
Appendix 2.1.1. 
Informed Consent 
The investigator is responsible for: 
• ensuring that the subject or the subject’s legal representative understands the 
nature of the study, the potential risks and benefits of participating in the study, 
and that their participation is voluntary. 
• ensuring that informed consent is given by each subject or legal representative.  
This includes obtaining the appropriate signatures and dates on the informed 
consent form (ICF) prior to the performance of any protocol procedures and 
prior to the administration of investigational product. 
• answering any questions the subject or the subject’s legal representative may 
have throughout the study and sharing in a timely manner any new information 
that may be relevant to the subject’s or the subject’s legal representative’s 
willingness to continue his or her participation in the study. 
• ensuring that a copy of the ICF is provided to the participant or the participant’s 
legal representative and is kept on file. 
• ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study and the 
date the written consent was obtained.  The authorized person obtaining the 
informed consent must also sign the ICF.  
Appendix 2.1.2. 
Recruitment 
Lilly is responsible for the central recruitment strategy for subjects.  Individual investigators may 
have additional local requirements or processes. 
Appendix 2.1.3. 
Ethical Review 
The investigator or an appropriate local representative must give assurance that the ethical 
review board (ERB) was properly constituted and convened as required by International Council 
for Harmonisation (ICH) guidelines and other applicable laws and regulations. 
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site(s).  Lilly or its representatives must approve the ICF, 
including any changes made by the ERBs, before it is used at the investigative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Practice (GCP). 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 44 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
The study site’s ERB(s) should be provided with the following: 
• the protocol and related amendments and addenda, current Investigator’s 
Brochure, United States Product Information, training checklist, and updates 
during the course of the study 
• the ICF 
• other relevant documents (for example, curricula vitae, advertisements) 
Appendix 2.1.4. 
Regulatory Considerations 
This study will be conducted in accordance with the protocol and with the: 
• consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines 
• applicable ICH GCP Guidelines 
• applicable laws and regulations 
Some of the obligations of the sponsor will be assigned to a third party. 
Appendix 2.1.5. 
Investigator Information 
Physicians with a specialty in endocrinology, diabetology, and/or primary care will participate as 
investigators in this clinical trial. 
Appendix 2.1.6. 
Protocol Signatures 
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative. 
Appendix 2.1.7. 
Final Report Signature 
The investigator will sign the final clinical study report (CSR) for this study, indicating 
agreement with the analyses, results, and conclusions of the report. 
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study. 
Appendix 2.2. 
Data Quality Assurance 
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following: 
• provide instructional material to the study sites, as appropriate 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 45 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
• sponsor start-up training to instruct the investigators and study coordinators.  This 
training will give instruction on the protocol, the completion of the case report 
forms (CRFs), and study procedures. 
• make periodic visits to the study site 
• be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax 
• review and evaluate CRF data and use standard computer edits to detect errors in 
data collection 
• conduct a quality review of the database 
In addition, Lilly or its representatives will periodically check a sample of the subject data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives, and/or regulatory agencies at any time.  Investigators will be given notice before 
an audit occurs. 
The investigator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents. 
Appendix 2.2.1. 
Data Capture System 
An electronic data capture system will be used in this study.  The site maintains a separate source 
for the data entered by the site into the sponsor-provided electronic data capture system. 
Paper and electronic patient-reported outcomes (ePRO) measures or other data reported directly 
by the subject are entered into an ePRO instrument at the time that the information is obtained.  
In these instances where there is no prior written or electronic source data at the site, the ePRO 
instrument record will serve as the source. 
If ePRO records are stored at a third-party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study 
for retention. 
Any data for which the ePRO instrument record will serve to collect source data will be 
identified and documented by each site in that site’s study file. 
Case report form data will be encoded and stored in a clinical trial database. 
Case report form data collected by a third party will be encoded by the third party and stored 
electronically in the third-party’s database system.  Validated data will subsequently be 
transferred to the sponsor’s data warehouse using standard Lilly file transfer processes. 
Any data for which paper documentation provided by the study participant will serve as the 
source document will be identified and documented by each site in that site’s study file.  Paper 
documentation provided by the study participant may include, for example, a paper diary to 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 46 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
collect patient-reported outcomes measures (for example, a rating scale), a daily dosing schedule, 
or an event diary. 
Data from complaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system. 
Appendix 2.3. 
Study and Site Closure 
Appendix 2.3.1. 
Discontinuation of Study Sites 
Study site participation may be discontinued if Lilly or its designee, the investigator, or the ERB 
of the study site judges it necessary for medical, safety, regulatory, or other reasons consistent 
with applicable laws, regulations, and GCP. 
Appendix 2.3.2. 
Discontinuation of the Study 
The study will be discontinued if Lilly or its designee judges it necessary for medical, safety, 
regulatory, or other reasons consistent with applicable laws, regulations, and GCP. 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 47 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Appendix 3. 
Classification of Contraceptive Methods 
Highly Effective Methods of Contraception: 
• Combined oral contraceptive pill and mini-pill 
• NuvaRing 
• Implantable contraceptives 
• Injectable contraceptives (such as Depo-Provera®) 
• Intrauterine device (such as Mirena® and ParaGard®) 
• Contraceptive patch – ONLY women <198 pounds or 90 kg 
• Total Abstinence 
• Vasectomy – for men in clinical trials 
Effective Methods of Contraception (must use combination of 2 methods): 
• Male condom with spermicide 
• Female condom with spermicide 
• Diaphragm with spermicide 
• Cervical sponge 
• Cervical cap with spermicide 
Ineffective Forms of Contraception – not acceptable as a method for clinical trials 
• Spermicide alone (please note spermicide alone is not considered a barrier method) 
• Immunocontraceptives 
• Periodic abstinence 
• Fertility awareness (calendar method, temperature method, combination of above 2, 
cervical mucus, symptothermal) 
• Withdrawal 
• Post coital douche 
• Lactational amenorrhea 
 
 

F3Z-MC-IOQV(a) Clinical Protocol 
Page 48 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Appendix 4. 
  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI

F3Z-MC-IOQV(a) Clinical Protocol 
Page 49 
LY8888AT 
 
 
 
Confidential 
 
 
 
 
Dated: 17 Nov 2017 
 
Appendix 5. 
Summary of Protocol Amendments 
Protocol Amendment 1, Dated 17 Nov 2017 
Section 
Summary of Changes 
2 Schedule of Activities 
Negative pregnancy test added as a required activity to be conducted 
during screening (Visit 1) 
6.1 Inclusion Criteria [5b] 
Definitions of women of child-bearing potential added to the 
inclusion criteria 
Appendix 3 
Classification of contraceptive methods added 
Appendix 4 –
  
Information on 
 and the use of mobile nurses 
 
CCI
CCI